Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 9/20 | 0.59 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.47 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.47 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.47 |
| ▸ | SALL4 | Q9UJQ4 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | IL1B | P01584 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30550160 | 1.00 | MAP1LC3B (0.59) | MAP1LC3BSTAT3CRBNCSNK1A1IKZF1 | |
| SCHEMBL21792624 | 0.91 | MAP1LC3B (0.66) | MAP1LC3BCRBNCSNK1A1IKZF1IKZF3 | |
| SCHEMBL26200447 | 0.91 | MAP1LC3B (0.60) | MAP1LC3BSTAT3CRBNCSNK1A1IKZF1 | |
| SCHEMBL30891789 | 0.90 | STAT3 (0.53) | MAP1LC3BSTAT3CRBNBRD4 | |
| SCHEMBL30891811 | 0.90 | STAT3 (0.53) | MAP1LC3BSTAT3CRBNBRD4 | |
| SCHEMBL28668320 | 0.90 | STAT3 (0.53) | MAP1LC3BSTAT3CRBNCSNK1A1IKZF3 | |
| SCHEMBL25031848 | 0.89 | MAP1LC3B (0.52) | MAP1LC3BSTAT3CRBNCSNK1A1IKZF3 | |
| SCHEMBL23772670 | 0.89 | MAP1LC3B (0.51) | MAP1LC3BSTAT3CRBNIKZF1IKZF3 | |
| SCHEMBL23772439 | 0.89 | MAP1LC3B (0.51) | MAP1LC3BSTAT3CRBNIKZF1IKZF3 | |
| SCHEMBL23772825 | 0.89 | MAP1LC3B (0.51) | MAP1LC3BSTAT3CRBNIKZF1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163066-A1 | PROTACs of MALT1 | TEGID THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2023164175-A2 | PROTACS OF MALT1 | TEGID THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163066-A1 | PROTACs of MALT1 | MALT1, BCL3, BCL9 | MAP1LC3B 115/4885STAT3 3600/4885CRBN 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.